Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis

Mostrar otras versiones (1)

Introduction: Data are limited on antibody response to the ChAdOx1 nCoV-19 vaccine (AZD1222; Covishield(®)) in cirrhosis. We studied the antibody response following two doses of the ChAdOx1 vaccine, given 4–12 weeks apart, in cirrhosis. Methods: Prospectively enrolled, 131 participants (71% males; a...

Descripción completa

Detalles Bibliográficos
Autores principales: Goel, Amit, Verma, Alka, Tiwari, Prachi, Katiyar, Harshita, Aggarwal, Amita, Khetan, Dheeraj, Mayank, Kishore, Ravi V. Krishna, Kumar, Pankaj, Singh, Thakur Prashant, Sheikh, Sabreena, Vaishnav, Manas, Pathak, Piyush, Shalimar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696004/
https://www.ncbi.nlm.nih.gov/pubmed/36366346
http://dx.doi.org/10.3390/vaccines10111837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696004/
https://www.ncbi.nlm.nih.gov/pubmed/36366346
http://dx.doi.org/10.3390/vaccines10111837

Ejemplares similares